Treatment of alzheimer's disease
A method for the treatment of Alzheimer's disease in a subject having or suspected of having Alzheimer's disease by administering to the subject a therapeutically effective amount of an antibody wherein the antibody is raised against a protofibril that contains an Aβ-Arc peptide.
1. A method for the treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody wherein said antibody is raised against a protofibril comprising an Aβ-Arc peptide selected from the group consisting of Aβ39-Arc (Amino Acids 1–39 of SEQ ID NO:1), Aβ40-Arc (Amino Acids 1–40 of SEQ ID NO:1), and Aβ42-Arc (SEQ ID NO:1), wherein said antibodies bind to arctic and wild-type Aβ peptides in protofibril conformation.
2. A method for the treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a protofibril comprising an Aβ-Arc peptide selected from the group consisting of Aβ39-Arc (Amino Acids 1–39 of SEQ ID NO:1), Aβ40-Arc (Amino Acids 1–40 of SEQ ID NO:1), Aβ41-Arc (Amino Acids 1–41 of SEQ ID NO:1), Aβ42-Arc (SEQ ID NO:1), and combinations thereof, wherein said antibodies bind to arctic and wildtype Aβ peptides in protofibril conformation.
3. The method according to claim 2 , wherein said protofibril further comprises an Aβ peptide having a mutation selected from the group consisting of the Dutch, Flemish, Italian, Iowa mutations, and combinations thereof.
4. The method according to claim 2 , wherein said antibody is monoclonal.
5. The method according to claim 2 , wherein said antibody is human or humanized.
6. The method according to claim 2 , wherein said protofibril further comprises an Aβ peptide having a Dutch mutation.
7. The method according to claim 2 , wherein said Aβ-Arc peptide is Aβ39-Arc (Amino Acids 1–39 of SEQ ID NO:1).
8. The method according to claim 2 , wherein said Aβ-Arc peptide is Aβ40-Arc (Amino Acids 1–40 of SEQ ID NO:1).
9. The method according to claim 2 , wherein said Aβ-Arc peptide is Aβ41-Arc (Amino Acids 1–41 of SEQ ID NO:1).
10. The method according to claim 2 , wherein said Aβ-Arc peptide is Aβ42-Arc (SEQ ID NO:1).
11. A method for the treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a composition comprising a protofibril comprising an Aβ-Arc peptide selected from the group consisting of Aβ39-Arc (Amino Acids 1–39 of SEQ ID NO:1), Aβ40-Arc (Amino Acids 1–40 of SEQ ID NO:1), Aβ41-Arc (Amino Acids 1–41 of SEQ ID NO:1), Aβ42-Arc (SEQ ID NO:1), and combinations thereof, wherein said antibodies bind to arctic and wild-type Aβ peptides in protofibril conformation.
12. The method according to claim 11 , wherein said antibody is monoclonal.
13. The method according to claim 11 , wherein said antibody is human or humanized.
14. The method according to claim 11 , wherein said protofibril further comprises an Aβ peptide with a mutation selected from the group consisting of the Dutch, Flemish, Italian and Iowa mutations.
15. The method according to claim 11 , wherein said Aβ-Arc peptide is Aβ39-Arc (Amino Acids 1–39 of SEQ ID NO:1).
16. The method according to claim 11 , wherein said Aβ-Arc peptide is Aβ40-Arc (Amino Acids 1–40 of SEQ ID NO:1).
17. The method according to claim 11 , wherein said Aβ-Arc peptide is Aβ-Arc (SEQ ID NO:1).
18. The method according to claim 11 , wherein said Aβ-Arc peptide is Aβ41-Arc (Amino Acids 1–41 of SEQ ID NO:1).